Q-omics provides the consensus-scored STX5 profile across patient tissues and cancer cell-line models. STX5 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, STX5 is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, STX5 RNA expression shows 18,332 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and LIHC as cancer lineages where STX5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STX5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STX5 survival associations across molecular data types. STX5 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STX5 RNA expression–survival associations across cancer types. High STX5 expression shows unfavorable associations in ACC, KICH, PAAD and BLCA, but favorable associations in THYM and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for STX5 RNA expression.
This table summarizes STX5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for STX5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STX5 shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, HNSC, KIRC and COAD. The LIHC box plot shows higher STX5 RNA expression in tumor versus normal tissue (log2 FC = +0.799, t-test p < 0.001).
This table shows molecular features associated with STX5 in patient tissues and cancer cell lines. In patient samples, STX5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, STX5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BONE and LUNG_NSCLC_LUAD.
